ANRO News

Latest breaking news and updates for ANRO stock.

Track all markets on TradingView

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

NEW YORK, Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the ...

Will the deadline of September 19, 2025 influence short‑term trading activity or prompt a re‑assessment of risk for current investors? What potential financial exposure does the lawsuit present for ANRO and could it trigger a material adverse change? How likely is it that shareholders will be selected as lead plaintiffs and what effect could that have on ANRO's valuation?
Lawsuits
2 days ago
Read more prnewswire

ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Alto Neuroscience, Inc. ("...

How might this legal action influence investor sentiment and the company's valuation relative to its peers? What potential financial liabilities or settlement costs could arise from the securities fraud case? How will the lawsuit affect ANRO's short-term stock volatility and trading volume?
Lawsuits
2 days ago
Read more prnewswire

Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO

NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and certain officer...

Are there precedent lawsuits in the neuroscience sector that could indicate the outcome or settlement size? What is the likely short‑term impact on ANRO’s share price and trading volume? How significant is the potential liability from the class action and could it affect ANRO's balance sheet?
Lawsuits
4 days ago
Read more prnewswire

Alto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ANRO

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Alto Neuroscience, Inc. ("Alto Neuroscience, Inc." or the "Company") (NYSE: ANRO) of a class action securities la...

What are the potential repercussions for the company’s existing partnerships and collaborations? How might this litigation influence the company’s R&D pipeline and product timelines? Are any key executives or directors personally named or at risk in the lawsuit?
Lawsuits
5 days ago
Read more prnewswire

ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. Securities Fraud Lawsuit

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable ...

What is the expected impact on the stock’s short‑interest and potential for a short‑squeeze scenario? How will the legal proceedings affect the company’s operational focus and R&D timelines for its neuroscience programs? Are there any indications of the lawsuit’s timeline that could affect upcoming earnings releases or key milestones?
Lawsuits
6 days ago
Read more prnewswire

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the ...

How does this litigation risk compare to those faced by ANRO's competitors in the neurotech space? Is there a risk of a short squeeze or increased short interest due to this litigation news? Could the lawsuit impact the company’s ability to secure partnerships or funding?
Lawsuits
6 days ago
Read more prnewswire

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel p...

Are there upcoming catalyst events (e.g., data readouts, conference presentations) that could move the stock? What is the projected impact on revenue and profitability if the pipeline progresses as expected? How does the reported sentiment score of 60 compare to prior releases and overall market sentiment?
Earnings
7 days ago
Read more businesswire